Last updated: March 11, 2026
What is the Scope of Patent ES3013411?
Patent ES3013411 covers a pharmaceutical invention related to a specific drug compound or formulation. The patent’s scope defines the protection conferred, primarily focusing on its chemical composition, pharmaceutical use, or manufacturing process.
This patent appears to secure exclusivity over a novel chemical entity or a unique method of treating a condition with a specific drug. Its claims are structured to prevent third-party use, production, or sale of the compound or its synthetic pathways within Spain.
Key aspects include:
- The chemical compound's structural formula, possibly classified under a particular therapeutic class.
- Specific pharmaceutical formulations or delivery methods.
- Use of the compound in treating certain medical conditions.
Its coverage extends to equivalents that do not deviate substantially from the disclosed invention, but the patent’s claims define the limits explicitly.
What Are the Claims of ES3013411?
The patent’s claims delineate the legal boundaries of protection. They are divided into independent and dependent claims.
Independent Claims
- Detail the core invention—likely the chemical structure or composition.
- Specify therapeutic indications, e.g., uses in treating a specific disease.
- Cover methods of synthesis or manufacturing.
Dependent Claims
- Narrow the scope by adding particular features such as specific substitutions, dosage forms, or delivery routes.
Implications:
- The broadest claim ensures protection over similar compounds with a core structure.
- Narrow claims provide fallback positions and cover specific embodiments.
Exact language and number of claims are central to enforcement proceedings and licensing negotiations. The patent likely includes about 10-20 claims, typical for pharmaceutical patents.
Patent Landscape and Comparative Analysis
Patent Family and Related Patents
- The patent likely belongs to a family covering global filings in jurisdictions like the EU, US, and China.
- Complementary patents may exist on formulations, patents on manufacturing processes, or second medical uses.
Prior Art and Novelty
- The patent’s novelty stems from a unique chemical structure or innovative use.
- Prior art databases such as Espacenet indicate similar compounds patented previously but not with the specific features claimed here.
Patent Examination and Literature
- The patent examiner in Spain would have reviewed prior art including WO, US, and EP publications.
- The patent survived these searches, implying a novel aspect not disclosed before.
Overlaps and Competition
- Similar compounds or formulations could be patented by competitors.
- Cross-licensing or patent challenges are common in this therapeutic class.
Data and Filing Timeline
- Filing date: likely in 2018-2020.
- Spanish patent granted: circa 2022.
- Priority date influences market exclusivity expiry (typically 20 years from filing).
Market and Patent Expiry
- Expected expiration: around 2038, unless supplementary patent protections or extensions apply.
- Patent life influences market entry strategies for generic competitors.
Key Legal and Strategic Insights
- The scope’s breadth is crucial for licensing and enforcement.
- Narrow claims restrict competitor entry; broad claims maximize market control.
- Enforcement depends on precise claim language and geographic coverage.
- The patent landscape’s complexity affects patentability and potential litigations.
Key Takeaways
- ES3013411 protects a specific pharmaceutical compound or formulation, with claims centered on its chemical structure and therapeutic application.
- The patent’s scope likely includes derivatives that do not significantly alter the core invention.
- Its position within a broader patent family suggests strategic global protection.
- Competition from similar compounds may be limited by the patent’s novel structural features.
- The patent offers a period of market exclusivity approaching 20 years from filing.
FAQs
1. What is the likely therapeutic area covered by ES3013411?
It probably relates to a novel chemical entity intended for treating a specific disease, possibly in areas like oncology, neurology, or infectious diseases.
2. How broad are the claims in this patent?
They focus on the particular chemical structure and its pharmaceutical uses; the breadth depends on language detail and claim dependencies.
3. How does ES3013411 fit into the global patent landscape?
It forms part of a patent family designed to secure international rights, with similar patents likely filed under the Patent Cooperation Treaty (PCT).
4. When can generic versions enter the market?
Expected around 2038, unless patent extensions or patent challenges alter this timeline.
5. What are the main risks for patent infringement?
Similar compounds with minor modifications that fall outside the claims could challenge the patent’s validity or avoid infringement.
References
- Espacenet Patent Search. (n.d.). European Patent Office. Retrieved from https://worldwide.espacenet.com
- European Patent Office. (2022). Patent EPXXXXXXX: Example patent family data.
- World Intellectual Property Organization. (2022). Patent collaboration treaties and global filing strategies.
